SITE Centers Announces Sale of The Pike Outlets and Special Common Distribution
SITE Centers Reports First Quarter 2026 Results
SITE Centers Announces Sale of Meadowmont Crossing
SITE Centers' First Quarter 2026 Earnings to be Released Thursday, May 7, 2026
SITE Centers Announces Sale of 3030 North Broadway
REIT Replay: U.S. REIT Indexes Outperform Broader Market During Last Week Of Feb.
SITE Centers Announces Sale of FlatAcres MarketCenter
SITE Centers Reports Fourth Quarter and Full-Year 2025 Results
SITE Centers' Fourth Quarter 2025 Earnings to be Released Thursday, February 26, 2026
SITE Centers Announces Tax Allocations of 2025 Dividend Distributions
SITE Centers Announces Sale of Partnership Interests
U.S. Equity REITs Trade At Median 15% Discount To Analyst Price Targets
SITE Centers Announces Sale of Perimeter Pointe
REIT Replay: U.S. REIT Indexes Fall During Week Ended Dec. 19
Caxton Associates LLP Sells 219,046 Shares of Site Centers Corp. $SITC
SITE Centers Announces Sale of Downtown Short Pump
Fisher Asset Management LLC Sells 182,310 Shares of Site Centers Corp. $SITC
SITE Centers Provides Update on Disposition Activity and Go Forward Plan
SITE Centers Announces Special Common Stock Distribution and Debt Payoff
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 14,531 Shares of Site Centers Corp. $SITC
SITE Centers Announces Sales of Four Properties
SITE Centers Announces Sale of Paradise Village Gateway
REIT Replay: REIT Indexes Outperform Broader Markets During 1st Week Of November
Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
SITE Centers Reports Third Quarter 2025 Results
REIT Replay: REIT Indexes Close Final Week Of October In The Red
Candel Therapeutics to highlight immunotherapy advances at SITC 2025
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SITE Centers Announces Sale of Parker Pavilions
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Allianz Asset Management GmbH Sells 49,817 Shares of Site Centers Corp. $SITC
SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025